Vaxcyte slips as investors digest recent financing after Phase 3 vaccine data

Vaxcyte (PCVX) is down 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued digestion of Vaxcyte’s large early-October financing, which came just after a major clinical update. There does not appear to be a fresh company-specific negative announcement today, so the pullback looks more like financing-related pressure and profit-taking after a sharp rally earlier this month. This could be because investors are reassessing dilution and convertible note overhang while waiting for the next VAX-31 milestones.

Details:

Earlier in October, Vaxcyte reported positive topline results from the Phase 3 OPUS-1 trial for VAX-31, a key adult pneumococcal vaccine candidate.

On the same date, the company announced concurrent public offerings of common stock, pre-funded warrants and convertible senior notes to raise capital for development, manufacturing scale-up and launch preparation.

Vaxcyte later priced and then closed those offerings, with the combined transaction totaling about $1.15 billion, increasing the market’s focus on dilution and future conversion risk.

Today’s move happened without an obvious new corporate catalyst, which suggests the stock may be trading on positioning, recent issuance effects and near-term biotech volatility.

Sources:

Vaxcyte, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PCVX Insider Trading Activity

$PCVX insiders have traded $PCVX stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.

Here’s a breakdown of recent trading of $PCVX stock by insiders over the last 6 months:

GRANT PICKERING (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 19 sales selling 66,896 shares for an estimated $3,634,849.
JIM WASSIL (EVP, Chief Scientific Ofc, COO) has made 0 purchases and 15 sales selling 33,192 shares for an estimated $2,424,751.
ELVIA COWAN (SVP, Finance & CAO) sold 19,000 shares for an estimated $1,648,060
ANDREW GUGGENHIME (PRESIDENT AND CFO) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $1,641,716.
HARPREET S. DHALIWAL (Chief Technical Ops Officer) sold 17,000 shares for an estimated $935,068

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$PCVX Hedge Fund Activity

We have seen 181 institutional investors add shares of $PCVX stock to their portfolio, and 139 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,524,774 shares (+82.7%) to their portfolio in Q2 2026, for an estimated $321,155,112
FMR LLC added 4,360,046 shares (+26.4%) to their portfolio in Q2 2026, for an estimated $253,449,473
PARADIGM BIOCAPITAL ADVISORS LP removed 2,665,168 shares (-55.6%) from their portfolio in Q2 2026, for an estimated $154,926,215
PRICE T ROWE ASSOCIATES INC /MD/ added 2,012,570 shares (+206.1%) to their portfolio in Q2 2026, for an estimated $116,990,694
D. E. SHAW & CO., INC. removed 1,729,181 shares (-47.6%) from their portfolio in Q2 2026, for an estimated $100,517,291
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,464,812 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,149,521
WELLINGTON MANAGEMENT GROUP LLP added 1,386,968 shares (+24.7%) to their portfolio in Q2 2026, for an estimated $80,624,449

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PCVX Congressional Stock Trading

Members of Congress have traded $PCVX stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PCVX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 07/16, 05/13, 05/12 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.